Search Results | Cancer Research | American Association for Cancer Research

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Abstract 1624: Immune cell killing assay for measuring the effects of immunomodulating agents in lung cancer cells in vitro

Jenni H. Mäki-Jouppila, Jukka P. Rissanen, Katja M. Fagerlund

Cancer Res (2022) 82 (12_Supplement): 1624.

DOI: https://doi.org/10.1158/1538-7445.AM2022-1624

Published: 15 June 2022

View article

Journal Articles

Abstract 5202: Additive benefits of radium-223 dichloride and bortezomib combination in a syngeneic 5TGM1 multiple myeloma mouse model

Mari I. Suominen, Jukka P. Rissanen, Anniina Luostarinen, Katja M. Fagerlund, Birgitta Sjöholm, Esa Alhoniemi, Sanna-Maria Käkönen, Dominik Mumberg, Jussi M. Halleen, Karl Ziegelbauer, Arne Scholz

Cancer Res (2017) 77 (13_Supplement): 5202.

DOI: https://doi.org/10.1158/1538-7445.AM2017-5202

Published: 01 July 2017

View article

Journal Articles

Abstract 786: Effects of combination treatment with cabozantinib and bortezomib in the 5TGM1 murine multiple myeloma model

Mari I. Suominen, Katja M. Fagerlund, Esa Alhoniemi, Jukka P. Rissanen, Jussi M. Halleen, Dana T. Aftab

Cancer Res (2015) 75 (15_Supplement): 786.

DOI: https://doi.org/10.1158/1538-7445.AM2015-786

Published: 01 August 2015

View article

Journal Articles

Abstract 3447: Radium-223 dichloride exhibits dual mode-of-action inhibiting both tumor and tumor-induced bone growth in two osteoblastic prostate cancer models

Mari I. Suominen, Katja M. Fagerlund, Jukka P. Rissanen, Yvonne Konkol, Jukka Morko, Zhiqi Peng, Esa Alhoniemi, Dominik Mumberg, Karl Ziegelbauer, Sanna-Maria Käkönen, Jussi M. Halleen, Robert L. Vessella, Arne Scholz

Cancer Res (2015) 75 (15_Supplement): 3447.

DOI: https://doi.org/10.1158/1538-7445.AM2015-3447

Published: 01 August 2015

View article

Journal Articles

Abstract 734: Effects of Cabozantinib in the 5TGM1 murine multiple myeloma model

Mari I. Suominen, Douglas O. Clary, Rami Käkönen, Katja M. Fagerlund, Esa Alhoniemi, Jukka P. Rissanen, Jussi M. Halleen, Dana T. Aftab

Cancer Res (2014) 74 (19_Supplement): 734.

DOI: https://doi.org/10.1158/1538-7445.AM2014-734

Published: 01 October 2014

View article

Journal Articles

Abstract 4022: Combination of PI3K inhibitor BAY 1082439 with radium-223 is a promising treatment of cancer with bone metastases

Mari I. Suominen, Katja Fagerlund, Enrico Stasik, Andrea Haegebarth, Arne Scholz, Jukka P. Rissanen, Martin Kornacker, Dominik Mumberg, Jussi M. Halleen, Karl Ziegelbauer, Ningshu Liu

Cancer Res (2014) 74 (19_Supplement): 4022.

DOI: https://doi.org/10.1158/1538-7445.AM2014-4022

Published: 01 October 2014

View article

Journal Articles

Abstract 1803: A new spectrum-selective cathepsin inhibitor, VBY-825, inhibits bone destruction in a syngeneic 5TGM1 multiple myeloma mouse model

Mari I. Suominen, Johanna Tuomela, Esa Alhoniemi, Katja M. Fagerlund, Jukka P. Rissanen, Jussi M. Halleen, Leslie J. Holsinger

Cancer Res (2014) 74 (19_Supplement): 1803.

DOI: https://doi.org/10.1158/1538-7445.AM2014-1803

Published: 01 October 2014

View article

Journal Articles

Abstract LB-105: Radium-223 dichloride monotherapy and combination therapy with zoledronic acid or doxorubicin improve survival in a mouse model of breast cancer bone metastasis.

Mari I. Suominen, Jukka P. Rissanen, Rami Kakonen, Katja M. Fagerlund, Esa Alhoniemi, Dominik Mumberg, Karl Ziegelbauer, Jussi M. Halleen, Sanna-Maria Kakonen, Arne Scholz

Cancer Res (2013) 73 (8_Supplement): LB-105.

DOI: https://doi.org/10.1158/1538-7445.AM2013-LB-105

Published: 15 April 2013

View article

Journal Articles

Abstract 3842: Culturing cancer cells on myoma tissue: Development of a novel fully human organotypic 3D invasion model applicable as a preclinical tool for cancer drug development.

Jukka P. Rissanen, Katja M. Fagerlund, Johanna M. Tuomela, Mari I. Suominen, Jussi M. Halleen, Tuula A. Salo

Cancer Res (2013) 73 (8_Supplement): 3842.

DOI: https://doi.org/10.1158/1538-7445.AM2013-3842

Published: 15 April 2013

View article

Journal Articles

Abstract 5712: Alpharadin (Radium-223 chloride) completely prevents tumor growth in bone and increases survival in a mouse model of breast cancer bone metastases in preventive and micro-metastatic settings

Mari I. Suominen, Jukka P. Rissanen, Rami Käkönen, Dominik Mumberg, Karl Ziegelbauer, Jussi M. Halleen, Arne Scholz

Cancer Res (2012) 72 (8_Supplement): 5712.

DOI: https://doi.org/10.1158/1538-7445.AM2012-5712

Published: 15 April 2012

View article

Journal Articles

Abstract 2664: Alpharadin inhibits osteoclast differentiation in vitro and progression of established breast cancer bone metastases in vivo

Mari I. Suominen, Jukka P. Rissanen, Rami Käkönen, Dominik Mumberg, Karl Ziegelbauer, Jussi M. Halleen, Arne Scholz

Cancer Res (2011) 71 (8_Supplement): 2664.

DOI: https://doi.org/10.1158/1538-7445.AM2011-2664

Published: 15 April 2011

View article

Journal Articles

Abstract 845: Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis

Sirkku Pollari, Rami Käkönen, Khalid S. Mohammad, Jukka P. Rissanen, Jussi Halleen, Anni Wärri, Liisa Nissinen, Marjo Pihlavisto, Anne Marjamäki, Merja Perälä, Theresa Guise, Olli Kallioniemi, Sanna-Maria Käkönen

Cancer Res (2011) 71 (8_Supplement): 845.

DOI: https://doi.org/10.1158/1538-7445.AM2011-845

Published: 15 April 2011

View article

Journal Articles

Abstract 5394: Sequential treatment with zoledronic acid and doxorubicin has no additive effects in an established mouse model of bone metastasis

Mari I. Suominen, Rami Käkönen, Jukka P. Rissanen, Sanna-Maria Käkönen, Jussi M. Halleen

Cancer Res (2010) 70 (8_Supplement): 5394.

DOI: https://doi.org/10.1158/1538-7445.AM10-5394

Published: 15 April 2010

View article

NARROW

Abstract 1624: Immune cell killing assay for measuring the effects of immunomodulating agents in lung cancer cells in vitro

Abstract 5202: Additive benefits of radium-223 dichloride and bortezomib combination in a syngeneic 5TGM1 multiple myeloma mouse model

Abstract 786: Effects of combination treatment with cabozantinib and bortezomib in the 5TGM1 murine multiple myeloma model

Abstract 3447: Radium-223 dichloride exhibits dual mode-of-action inhibiting both tumor and tumor-induced bone growth in two osteoblastic prostate cancer models

Abstract 734: Effects of Cabozantinib in the 5TGM1 murine multiple myeloma model

Abstract 4022: Combination of PI3K inhibitor BAY 1082439 with radium-223 is a promising treatment of cancer with bone metastases

Abstract 1803: A new spectrum-selective cathepsin inhibitor, VBY-825, inhibits bone destruction in a syngeneic 5TGM1 multiple myeloma mouse model

Abstract LB-105: Radium-223 dichloride monotherapy and combination therapy with zoledronic acid or doxorubicin improve survival in a mouse model of breast cancer bone metastasis.

Abstract 3842: Culturing cancer cells on myoma tissue: Development of a novel fully human organotypic 3D invasion model applicable as a preclinical tool for cancer drug development.

Abstract 5712: Alpharadin (Radium-223 chloride) completely prevents tumor growth in bone and increases survival in a mouse model of breast cancer bone metastases in preventive and micro-metastatic settings

Abstract 2664: Alpharadin inhibits osteoclast differentiation in vitro and progression of established breast cancer bone metastases in vivo

Abstract 845: Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis

Abstract 5394: Sequential treatment with zoledronic acid and doxorubicin has no additive effects in an established mouse model of bone metastasis

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only